News in Brief

UK site acquisition strengthens KD Pharma’s omega-3 capacity

04-Jun-2019 - Last updated on 04-Jun-2019 at 10:59 GMT

Global omega-3 player KD Pharma says the new site at Seal Sands will expand its capacity for manufacturing omega-3-based intermediates, especially for those use in producing active pharmaceutical ingredients (APIs).

The facility, close to Middlesbrough, UK, was previously used for manufacturing omega-3 products.

“This acquisition expands our technology and manufacturing base for producing APIs with the highest concentrations of EPA and DHA omega-3s,” commented Oscar Groet, CEO of KD Pharma Group.

KD Pharma said it strives to be the leading manufacturer in the rapidly growing omega-3 API market.

“The breadth of our technology platform sets KD Pharma apart, no company has more technologies for isolating and fractionating lipids,” added Groet.

The UK site acquisition will enable it to meet market demand for the highest quality APIs in response to new product approvals, label expansions, and supportive clinical research, said the firm.

The company says the site will be brought online this year and operated alongside its other manufacturing sites in Bexbach, Germany; Brattvag, Norway; and Miami, United States.